Literature DB >> 17914440

Vaccine immunopotentiators of the future.

V E J C Schijns1, W G J Degen.   

Abstract

Vaccine adjuvants or immunopotentiators comprise a diverse group of molecules or formulations. Despite a wealth of different candidates, there is a need for better vaccine adjuvants in both veterinary and human medicine. For human vaccines, the immunopotentiator choice has been limited to aluminum salts, until recently. By contrast, a whole range of adjuvants is employed for inactivated veterinary vaccines, due to less stringent safety and regulatory requirements and proven superior vaccine performance. This review highlights recent developments and future trends in immunopotentiators.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17914440     DOI: 10.1038/sj.clpt.6100394

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  15 in total

Review 1.  Toll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responses.

Authors:  Egest J Pone; Hong Zan; Jingsong Zhang; Ahmed Al-Qahtani; Zhenming Xu; Paolo Casali
Journal:  Crit Rev Immunol       Date:  2010       Impact factor: 2.214

Review 2.  Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns.

Authors:  Martin F Bachmann; Gary T Jennings
Journal:  Nat Rev Immunol       Date:  2010-10-15       Impact factor: 53.106

Review 3.  Immunotherapy of malignant gliomas using autologous and allogeneic tissue cells.

Authors:  F M Hofman; A Stathopoulos; C A Kruse; T C Chen; V E J C Schijns
Journal:  Anticancer Agents Med Chem       Date:  2010-07       Impact factor: 2.505

Review 4.  Design opportunities for actively targeted nanoparticle vaccines.

Authors:  Tarek M Fahmy; Stacey L Demento; Michael J Caplan; Ira Mellman; W Mark Saltzman
Journal:  Nanomedicine (Lond)       Date:  2008-06       Impact factor: 5.307

5.  Delivery of foreign antigens by engineered outer membrane vesicle vaccines.

Authors:  David J Chen; Nikolaus Osterrieder; Stephan M Metzger; Elizabeth Buckles; Anne M Doody; Matthew P DeLisa; David Putnam
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-27       Impact factor: 11.205

Review 6.  Current challenges for cancer vaccine adjuvant development.

Authors:  William S Bowen; Abhishek K Svrivastava; Lalit Batra; Hampartsoum Barsoumian; Haval Shirwan
Journal:  Expert Rev Vaccines       Date:  2018-02-08       Impact factor: 5.217

7.  In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination.

Authors:  Jagadeesh Bayry; Elma Z Tchilian; Matthew N Davies; Emily K Forbes; Simon J Draper; Srini V Kaveri; Adrian V S Hill; Michel D Kazatchkine; Peter C L Beverley; Darren R Flower; David F Tough
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-11       Impact factor: 11.205

8.  Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.

Authors:  Marco Tamborrini; Sabine A Stoffel; Nicole Westerfeld; Mario Amacker; Michael Theisen; Rinaldo Zurbriggen; Gerd Pluschke
Journal:  Malar J       Date:  2011-12-13       Impact factor: 2.979

9.  Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02.

Authors:  Meta Roestenberg; Ed Remarque; Erik de Jonge; Rob Hermsen; Hildur Blythman; Odile Leroy; Egeruan Imoukhuede; Soren Jepsen; Opokua Ofori-Anyinam; Bart Faber; Clemens H M Kocken; Miranda Arnold; Vanessa Walraven; Karina Teelen; Will Roeffen; Quirijn de Mast; W Ripley Ballou; Joe Cohen; Marie Claude Dubois; Stéphane Ascarateil; Andre van der Ven; Alan Thomas; Robert Sauerwein
Journal:  PLoS One       Date:  2008-12-18       Impact factor: 3.240

10.  Origins of injection-site sarcomas in cats: the possible role of chronic inflammation-a review.

Authors:  Kevin N Woodward
Journal:  ISRN Vet Sci       Date:  2011-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.